November 19, 2014
“LaunchTrends: Gilotrif Wave 3 (US)” is the third in a series of syndicated reports designed to track physician perception, uptake, and competitive environment regarding the newly launched non-…
LaunchTrends: Gilotrif is a series of three post-launch syndicated reports designed to track physician perception and uptake of newly launched Gilotrif (Boehringer Ingelheim’s afatinib)…
Based on a survey of 100 medical oncologists and 30 MCO pharmacy and medical directors, this report explores the market access challenges facing key current and emerging brands used in the…